Oxford Biomedica (LON:OXB) Given New GBX 380 Price Target at Deutsche Bank Aktiengesellschaft

Oxford Biomedica (LON:OXB) had its price target raised by Deutsche Bank Aktiengesellschaft from GBX 250 ($3.35) to GBX 380 ($5.09) in a report issued on Tuesday, LSE.Co.UK reports. The firm presently has a “hold” rating on the biopharmaceutical company’s stock. Deutsche Bank Aktiengesellschaft’s price objective would indicate a potential upside of 0.80% from the stock’s current price.

Oxford Biomedica Stock Up 4.7 %

LON:OXB traded up GBX 17 ($0.23) on Tuesday, hitting GBX 377 ($5.05). The stock had a trading volume of 314,716 shares, compared to its average volume of 206,863. The business’s fifty day moving average is GBX 347.48 and its 200 day moving average is GBX 299.34. The company has a market cap of £397.13 million, a PE ratio of -231.29 and a beta of 1.09. The company has a quick ratio of 1.67, a current ratio of 3.19 and a debt-to-equity ratio of 143.20. Oxford Biomedica has a 52 week low of GBX 164.29 ($2.20) and a 52 week high of GBX 394.50 ($5.28).

Oxford Biomedica Company Profile

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems.